2 results about "Dianhydrohexitol" patented technology

The present invention provides, in part, dianhydrohexitol-based cationic lipids of Formula (I), and sub-formulas thereof: (I), or a pharmaceutically acceptable salt thereof. The present invention also provides, in part, dianhydrohexitol-based cationic lipids of Formulae (IIA), and sub-formulas thereof: (IIA), or a pharmaceutically acceptable salt thereof. The present invention also provides, in part, dianhydrohexitol-based cationic lipids of Formulae (IIB), and sub-formulas thereof: (IIB), or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

The present disclosure relates to 1,4:3,6-dianhydrohexitol, specifically isosorbide, and compositions comprising 1,4:3,6-dianhydrohexitol for treating oral inflammatory conditions. These conditions, which include both oral mucosal inflammation and periodontal diseases, are characterized by elevated levels of pro-inflammatory mediators, particularly IL-1 alpha and IL-8. Using the EpiOral™ model, isosorbide has demonstrated significant ability to reduce IL-1 alpha secretion and IL-8 gene expression in inflamed oral epithelial cells. These results support its therapeutic relevance in treating oral inflammatory conditions through modulation of key inflammatory mediators.